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Background
Both BL and DLBCL are prevalent in HIV/AIDS patients
and the correct classification of these two subtypes of
Non-Hodgkin's lymphomas (NHL) particularly between
DLCBL with high proliferation and BL, is critical to chem-
otherapy choice. Transcriptional gene expression profiling
of sporadic and endemic BL by Stein et al (Berlin) identi-
fied a molecular signature for BL that included a down
regulation of CD44 expression in a group of lymphomas
from Africa. Immunophenotyping of formalin-fixed par-
affin-embedded (FFPE) BL tissues by this group demon-
strated difficulties in correctly classifying BL using
morphology, BCL-2 (immunohistochemistry – IHC) pres-
ence and MYC (fluorescent in situ hybridization – FISH)
absence. The differential expression of CD44, albeit non-
membranous, suggests an intricate regulatory circuit that
allows for low expression, supporting the possibility that
CD44 plays a role in BL/BLL dissemination. CD44 (IHC)
could be a valuable marker to aid classification of tumors
whose morphologic and phenotypic overlap is among BL,
BLL and DLBCL. CD44 absence clearly separates MYC+
BL/BLL and MYC-DLBCL. DLBCL, Hodgkin's lymphoma
(HL) and normal lymphocytes from lymphoid mantle/
marginal cell and interfollicular T-cell-rich zones should
be strongly CD44 positive.
Materials and methods
We evaluated 128 FFPE lymphoma tissue biopsy collected
at St. Mary's Lacor Hospital, Gulu, Uganda, Africa, from
1994 to 2007 from tissue microarray (TMA) blocks con-
structed on site using the UNITMA Quick-Ray System
(Seoul, South Korea). The completed TMA blocks were
sectioned and stained for H&E, IHC including: CD44,
CD43, CD45, CD45RO, MUM-1, CD138, TdT, CD5,
CD3, CD20, CD79a, CD10, BCL-2, BCL-6, KI67 (MIM-1),
HHV-8 (LANA-1), IgM, CD30, CD15, CD68, CD23,
Vimentin, CD34, EMA, CD34, Cyclin D1, BIM and p53; in
situ hybridization (ISH) for EBV (EBER) and kappa and
lambda light chains and FISH break apart assay for C-
MYC translocation.
Results
Of the 128 core samples collected (one per case), 107
could be interpreted. Ninety-two had results for CD44; 15
could not be read for CD44 due to missing tissue or necro-
sis. Seventy-one (66.4%) were negative for significant
CD44 staining of tumor cells. Included were: 53 BL, 10
Burkitt lymphoma-like (BLL) and eight other (two small
cell lymphomas, one marginal cell lymphoma, one lym-
phoblastic lymphoma, one follicular lymphoma, two
normal tissues and one alveolar rhabdomyosarcoma).
Twenty-one (19.6%) core samples were CD44 positive.
Included were four DLBCL and 17 other (two small cell
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lymphomas, one gut associated lymphoma, one anaplas-
tic large cell lymphoma, one histocyte rich lymphoma,
one peripheral T cell lymphoma, three lymph nodes, three
HD, two follicular lymphomas, and three normal tissues).
Of note, supporting tissue in some BLL samples were pos-
itive for CD44 unlike the BL group, but the BLL tumor
cells did not show membrane staining as seen with the
DLBCL cells. C-MYC (FISH) probe produced no signals in
the 42 biopsies collected prior to 2003. The 27 BL/BLL
samples from 2003 to 2007 were C-MYC positive (17 or
73.9%) or C-MYC negative (six or 26.1%) except for four
instances where the tissue core section was not present on
the test slide. DLBCL samples were C-MYC negative. Most
BL core sections (89.6%) and BLL core sections (90%)
were EBV positive while all DLBCL core sections were EBV
negative. The BL/BLL core sections were BCL-2 negative
and usually BCL-6 positive (87.5%).
Conclusion
CD44 absence on BL/BLL cells aligned C-MYC transloca-
tion, EBV-positive tumor cells and absence of BCL-2 with
the BL group. The DLBCL group was strongly positive for
CD44 cell membrane staining and variably positive for
BCL-2, MUM-1 and CD10. Where BL/BLL presented as
infiltrating cells into various supporting tissues rather
than as monomorphic tumor, CD44 staining was insuffi-
cient to distinguish the BL/BLL cells but could be used
along with other tests such as CD20 and BCL-6 to charac-
terize this subtype. Our results suggest that CD44 is of
value when used along with tumor cell morphology, as a
clarifying additional test or as a surrogate for C-MYC test-
ing in resource constrained settings to assure accurate sep-
aration of BL/BLL from DLBCL.Page 2 of 2
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